Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770–803. doi:10.1021/acs.jnatprod.9b01285
   PubMed Web of Science ®Google Scholar
• Dutta R, Khalil R, Green R, et al. (Ashwagandha) and Withaferin A: potential in Integrative Oncology. Int J Mol Sci. 2019;20(21):5310. doi:10.3390/ijms20215310
   PubMed Web of Science ®Google Scholar
• Farooqui AA, Farooqui T, Madan A, et al. Ayurvedic Medicine for the Treatment of Dementia: mechanistic Aspects. Evid Based Complement Alternat Med. 2018;2018:2481076. doi:10.1155/2018/2481076
   PubMed Web of Science ®Google Scholar
• Pratte MA, Nanavati KB, Young V, et al. An Alternative Treatment for Anxiety: a Systematic Review of Human Trial Results Reported for the Ayurvedic Herb Ashwagandha (Withania somnifera). J Altern Complement Med. 2014;20(12):901–908. doi:10.1089/acm.2014.0177
   PubMed Web of Science ®Google Scholar
• Singh RH, Narsimhamurthy K, Singh G. Neuronutrient impact of Ayurvedic Rasayana therapy in brain aging. Biogerontology. 2008;9(6):369–374. doi:10.1007/s10522-008-9185-z
   PubMed Web of Science ®Google Scholar
• Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Phytother Res. 1999;13(4):275–291. doi:10.1002/(SICI)1099-1573(199906)13:4<275::AID-PTR510>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Dar NJ, Hamid A, Ahmad M. Pharmacologic overview of Withania somnifera, the Indian Ginseng. Cell Mol Life Sci. 2015;72(23):4445–4460. doi:10.1007/s00018-015-2012-1
   PubMed Web of Science ®Google Scholar
• Bhat JA, Akther T, Najar RA, et al. Withania somnifera (L.) Dunal (Ashwagandha); current understanding and future prospect as a potential drug candidate. Front Pharmacol. 2022;13:1029123. doi:10.3389/fphar.2022.1029123
   PubMed Web of Science ®Google Scholar
• Straughn AR, Kakar SS. Withaferin A: a potential therapeutic agent against COVID-19 infection. J Ovarian Res. 2020;13(1):79. doi:10.1186/s13048-020-00684-x
   PubMed Web of Science ®Google Scholar
• Kim S-H, Singh SV. Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells. Cancer Prevent Res. 2014;7(7):738–747. doi:10.1158/1940-6207.CAPR-13-0445
   PubMed Web of Science ®Google Scholar
• Sehrawat A, Samanta SK, Hahm E-R, et al. Withaferin A-mediated apoptosis in breast cancer cells is associated with alterations in mitochondrial dynamics. Mitochondrion. 2019;47:282–293. doi:10.1016/j.mito.2019.01.003
   PubMed Web of Science ®Google Scholar
• Stan SD, Hahm E-R, Warin R, et al. Withaferin A Causes FOXO3a- and Bim-Dependent Apoptosis and Inhibits Growth of Human Breast Cancer Cells In vivo. Cancer Res. 2008;68(18):7661–7669. doi:10.1158/0008-5472.CAN-08-1510
   PubMed Web of Science ®Google Scholar
• Hahm E-R, Moura MB, Kelley EE, et al. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS One. 2011;6(8):e23354. doi:10.1371/journal.pone.0023354
   PubMed Web of Science ®Google Scholar
• Hahm E-R, Singh SV. Autophagy fails to alter withaferin A-mediated lethality in human breast cancer cells. Curr Cancer Drug Targets. 2013;13(6):640–650. doi:10.2174/15680096113139990039
   PubMed Web of Science ®Google Scholar
• Lee J, Hahm E-R, Marcus AI, et al. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. Mol Carcinog. 2015;54(6):417–429. doi:10.1002/mc.22110
   PubMed Web of Science ®Google Scholar
• Szarc Vel Szic K, Op de Beeck K, Ratman D, et al. Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells. PLoS One. 2014;9(2):e87850. doi:10.1371/journal.pone.0087850
   PubMed Web of Science ®Google Scholar
• Lee J, Sehrawat A, Singh SV. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat. 2012;136(1):45–56. doi:10.1007/s10549-012-2239-6
   PubMed Web of Science ®Google Scholar
• Thaiparambil JT, Bender L, Ganesh T, et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer. 2011;129(11):2744–2755. doi:10.1002/ijc.25938
   PubMed Web of Science ®Google Scholar
• Nagalingam A, Kuppusamy P, Singh SV, et al. Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer. Cancer Res. 2014;74(9):2617–2629. doi:10.1158/0008-5472.CAN-13-2081
   PubMed Web of Science ®Google Scholar
• Lu L, Shi W, Deshmukh RR, et al. Tumor necrosis factor-α sensitizes breast cancer cells to natural products with proteasome-inhibitory activity leading to apoptosis. PLoS One. 2014;9(11):e113783. doi:10.1371/journal.pone.0113783
   PubMed Web of Science ®Google Scholar
• Liu W, Barnette AR, Andreansky S, et al. ERBB2 Overexpression Establishes ERBB3-Dependent Hypersensitivity of Breast Cancer Cells to Withaferin A. Mol Cancer Ther. 2016;15(11):2750–2757. doi:10.1158/1535-7163.MCT-15-0932
   PubMed Web of Science ®Google Scholar
• Hahm ER, Lee J, Huang Y, et al. Withaferin a suppresses estrogen receptor-α expression in human breast cancer cells. Mol Carcinog. 2011;50(8):614–624. doi:10.1002/mc.20760
   PubMed Web of Science ®Google Scholar
• Zhang X, Mukerji R, Samadi AK, et al. Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells. BMC Complement Altern Med. 2011;11(1):84. doi:10.1186/1472-6882-11-84
   PubMedGoogle Scholar
• Antony ML, Lee J, Hahm E-R, et al. Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of β-tubulin. J Biol Chem. 2014;289(3):1852–1865. doi:10.1074/jbc.M113.496844
   PubMed Web of Science ®Google Scholar
• Samanta SK, Lee J, Hahm E-R, et al. Peptidyl-prolyl cis/trans isomerase Pin1 regulates withaferin A-mediated cell cycle arrest in human breast cancer cells. Mol Carcinog. 2018;57(7):936–946. doi:10.1002/mc.22814
   PubMed Web of Science ®Google Scholar
• Zhang X, Timmermann B, Samadi AK, et al. Withaferin a induces proteasome-dependent degradation of breast cancer susceptibility gene 1 and heat shock factor 1 proteins in breast cancer cells. ISRN Biochem. 2012;2012:707586. doi:10.5402/2012/707586
   PubMedGoogle Scholar
• Hahm ER, Singh SV. Withaferin A-induced apoptosis in human breast cancer cells is associated with suppression of inhibitor of apoptosis family protein expression. Cancer Lett. 2013;334(1):101–108. doi:10.1016/j.canlet.2012.08.026
   PubMed Web of Science ®Google Scholar
• Hahm ER, Lee J, Singh SV. Role of mitogen-activated protein kinases and Mcl-1 in apoptosis induction by withaferin A in human breast cancer cells. Mol Carcinog. 2014;53(11):907–916. doi:10.1002/mc.22050
   PubMed Web of Science ®Google Scholar
• Ghosh K, De S, Das S, et al. Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231. PLoS One. 2016;11(12):e0168488. doi:10.1371/journal.pone.0168488
   PubMed Web of Science ®Google Scholar
• Muniraj N, Siddharth S, Nagalingam A, et al. Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells. Carcinogenesis. 2019. doi:10.1093/carcin/bgz015
   PubMed Web of Science ®Google Scholar
• Grossman EA, Ward CC, Spradlin JN, et al. Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-cancer Natural Products. Cell Chem Biol. 2017;24(11):1368–1376.e4. doi:10.1016/j.chembiol.2017.08.013
   PubMed Web of Science ®Google Scholar
• Sari AN, Bhargava P, Dhanjal JK, et al. Combination of Withaferin-A and CAPE Provides Superior Anticancer Potency: bioinformatics and Experimental Evidence to Their Molecular Targets and Mechanism of Action. Cancers. 2020;12(5):1160. doi:10.3390/cancers12051160
   PubMed Web of Science ®Google Scholar
• Munagala R, Kausar H, Munjal C, et al. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis. 2011;32(11):1697–1705. doi:10.1093/carcin/bgr192
   PubMed Web of Science ®Google Scholar
• Lee DH, LIM I-H, SUNG E-G, et al. Withaferin A inhibits matrix metalloproteinase-9 activity by suppressing the Akt signaling pathway. Oncol Rep. 2013;30(2):933–938. doi:10.3892/or.2013.2487
   PubMed Web of Science ®Google Scholar
• Sherwood LC, Aqil F, Vadhanam MV, et al. Development of a goat model for evaluation of withaferin A: cervical implants for the treatment of cervical intraepithelial neoplasia. Exp Mol Pathol. 2017;103(3):320–329. doi:10.1016/j.yexmp.2017.11.008
   PubMed Web of Science ®Google Scholar
• Nile SH, Nile A, Gansukh E, et al. Subcritical water extraction of withanosides and withanolides from ashwagandha (Withania somnifera L) and their biological activities. Food Chem Toxicol. 2019;132:110659. doi:10.1016/j.fct.2019.110659
   PubMed Web of Science ®Google Scholar
• Kakar SS, Ratajczak MZ, Powell KS, et al. Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells. PLoS One. 2014;9(9):e107596. doi:10.1371/journal.pone.0107596
   PubMed Web of Science ®Google Scholar
• Kakar SS, Parte S, Carter K, et al. Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget. 2017;8(43):74494–74505. doi:10.18632/oncotarget.20170
   PubMedGoogle Scholar
• Kakar SS, Jala VR, Fong MY. Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines. Biochem Biophys Res Commun. 2012;423(4):819–825. doi:10.1016/j.bbrc.2012.06.047
   PubMed Web of Science ®Google Scholar
• Straughn AR, Kelm NQ, Kakar SS. Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass. Front Cell Dev Biol. 2021;9:636498. doi:10.3389/fcell.2021.636498
   PubMed Web of Science ®Google Scholar
• Straughn AR, Kakar SS. Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling. J Ovarian Res. 2019;12(1):115. doi:10.1186/s13048-019-0586-1
   PubMedGoogle Scholar
• Pistollato F, Calderón Iglesias R, Ruiz R, et al. The use of natural compounds for the targeting and chemoprevention of ovarian cancer. Cancer Lett. 2017;411:191–200. doi:10.1016/j.canlet.2017.09.050
   PubMed Web of Science ®Google Scholar
• Kakar SS, Worth CA, Wang Z, et al. DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. J Cancer Stem Cell Res. 2016;4.
   Google Scholar
• Fong MY, Jin S, Rane M, et al. Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One. 2012;7(7):e42265. doi:10.1371/journal.pone.0042265
   PubMed Web of Science ®Google Scholar
• Zhang X, Samadi AK, Roby KF, et al. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A. Gynecol Oncol. 2012;124(3):606–612. doi:10.1016/j.ygyno.2011.11.044
   PubMed Web of Science ®Google Scholar
• Perestelo NR, Llanos GG, Reyes CP, et al. Expanding the Chemical Space of Withaferin A by Incorporating Silicon To Improve Its Clinical Potential on Human Ovarian Carcinoma Cells. J Med Chem. 2019;62(9):4571–4585. doi:10.1021/acs.jmedchem.9b00146
   PubMed Web of Science ®Google Scholar
• Hahm ER, Singh SV. Cytoprotective autophagy induction by withaferin A in prostate cancer cells involves GABARAPL1. Mol Carcinog. 2020;59(10):1105–1115. doi:10.1002/mc.23240
   PubMed Web of Science ®Google Scholar
• Moselhy J, Suman S, Alghamdi M, et al. Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate Cancer. Neoplasia. 2017;19(6):451–459. doi:10.1016/j.neo.2017.04.005
   PubMed Web of Science ®Google Scholar
• Kumar R, Nayak D, Somasekharan SP. SILAC-based quantitative MS approach reveals Withaferin A regulated proteins in prostate cancer. J Proteomics. 2021;247:104334. doi:10.1016/j.jprot.2021.104334
   PubMed Web of Science ®Google Scholar
• Roy RV, Suman S, Das TP, et al. Withaferin A, a Steroidal Lactone from Withania somnifera, Induces Mitotic Catastrophe and Growth Arrest in Prostate Cancer Cells. J Nat Prod. 2013;76(10):1909–1915. doi:10.1021/np400441f
   PubMed Web of Science ®Google Scholar
• Nishikawa Y, Okuzaki D, Fukushima K, et al. Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells. PLoS One. 2015;10(7):e0134137. doi:10.1371/journal.pone.0134137
   PubMed Web of Science ®Google Scholar
• Kim SH, Singh KB, Hahm E-R, et al. Withania somnifera root extract inhibits fatty acid synthesis in prostate cancer cells. J Tradit Complement Med. 2020;10(3):188–197. doi:10.1016/j.jtcme.2020.02.002
   PubMedGoogle Scholar
• Setty Balakrishnan A, Nathan AA, Kumar M, et al. Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression. Prostate Int. 2017;5(2):75–83. doi:10.1016/j.prnil.2017.03.002
   PubMed Web of Science ®Google Scholar
• Kim SH, Hahm E-R, Singh KB, et al. RNA-seq reveals novel mechanistic targets of withaferin A in prostate cancer cells. Carcinogenesis. 2020;41(6):778–789. doi:10.1093/carcin/bgaa009
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Ranga RS, Burikhanov R, et al. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 2007;67(1):246–253. doi:10.1158/0008-5472.CAN-06-2430
   PubMed Web of Science ®Google Scholar
• Das TP, Suman S, Alatassi H, et al. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer. Cell Death Dis. 2016;7(2):e2111. doi:10.1038/cddis.2015.403
   PubMed Web of Science ®Google Scholar
• Siddique AA, Joshi P, Misra L, et al. 5,6-De-epoxy-5-en-7-one-17-hydroxy withaferin A, a new cytotoxic steroid from Withania somnifera L. Dunal leaves. Nat Prod Res. 2014;28(6):392–398. doi:10.1080/14786419.2013.871545
   PubMed Web of Science ®Google Scholar
• Um HJ, Min K-J, Kim DE, et al. Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. Biochem Biophys Res Commun. 2012;427(1):24–29. doi:10.1016/j.bbrc.2012.08.133
   PubMed Web of Science ®Google Scholar
• Choi MJ, Park EJ, Min KJ, et al. Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells. Toxicol In Vitro. 2011;25(3):692–698. doi:10.1016/j.tiv.2011.01.010
   PubMed Web of Science ®Google Scholar
• Xia S, Miao Y, Liu S. Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells. Biochem Biophys Res Commun. 2018;503(4):2363–2369. doi:10.1016/j.bbrc.2018.06.162
   PubMed Web of Science ®Google Scholar
• Choi BY, Kim B-W. Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity. J Cancer Prevention. 2015;20(3):185–192. doi:10.15430/JCP.2015.20.3.185
   PubMedGoogle Scholar
• Suman S, Das TP, Sirimulla S, et al. Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells. Oncotarget. 2016;7(12):13854–13864. doi:10.18632/oncotarget.7351
   PubMedGoogle Scholar
• Alnuqaydan AM, Rah B, Almutary AG, et al. Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells. Am J Cancer Res. 2020;10(3):799–815.
   PubMed Web of Science ®Google Scholar
• Chung SS, Wu Y, Okobi Q, et al. Proinflammatory Cytokines IL-6 and TNF- α Increased Telomerase Activity through NF- κ B/STAT1/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells. Mediators Inflamm. 2017;2017:5958429. doi:10.1155/2017/5958429
   PubMed Web of Science ®Google Scholar
• Das T, Roy KS, Chakrabarti T, et al. Withaferin A modulates the Spindle assembly checkpoint by degradation of Mad2-Cdc20 complex in colorectal cancer cell lines. Biochem Pharmacol. 2014;91(1):31–39. doi:10.1016/j.bcp.2014.06.022
   PubMed Web of Science ®Google Scholar
• Koduru S, Kumar R, Srinivasan S, et al. Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther. 2010;9(1):202–210. doi:10.1158/1535-7163.MCT-09-0771
   PubMed Web of Science ®Google Scholar
• Li X, Zhu F, Jiang J, et al. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Autophagy. 2016;12(9):1521–1537. doi:10.1080/15548627.2016.1191722
   PubMed Web of Science ®Google Scholar
• Yu Y, Hamza A, Zhang T, et al. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol. 2010;79(4):542–551. doi:10.1016/j.bcp.2009.09.017
   PubMed Web of Science ®Google Scholar
• Aliebrahimi S, Kouhsari SM, Arab SS, et al. Phytochemicals, withaferin A and carnosol, overcome pancreatic cancer stem cells as c-Met inhibitors. Biomed Pharmacother. 2018;106:1527–1536. doi:10.1016/j.biopha.2018.07.055
   PubMed Web of Science ®Google Scholar
• Liu X, Qi W, Cooke LS, et al. An analog of withaferin A activates the MAPK and glutathione “stress” pathways and inhibits pancreatic cancer cell proliferation. Cancer Invest. 2011;29(10):668–675. doi:10.3109/07357907.2011.626478
   PubMed Web of Science ®Google Scholar
• Gu M, Yu Y, Gunaherath GMKB, et al. Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells. Invest New Drugs. 2014;32(1):68–74. doi:10.1007/s10637-013-9987-y
   PubMed Web of Science ®Google Scholar
• Li X, Zhu F, Jiang J, et al. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells. Cancer Lett. 2015;357(1):219–230. doi:10.1016/j.canlet.2014.11.026
   PubMed Web of Science ®Google Scholar
• Shiragannavar VD, Gowda NGS, Kumar DP, et al. Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC. Front Oncol. 2020;10:628506. doi:10.3389/fonc.2020.628506
   PubMed Web of Science ®Google Scholar
• Siddharth S, Muniraj N, Saxena N, et al. Concomitant Inhibition of Cytoprotective Autophagy Augments the Efficacy of Withaferin A in Hepatocellular Carcinoma. Cancers. 2019;11(4):453. doi:10.3390/cancers11040453
   PubMed Web of Science ®Google Scholar
• Hsu JH. Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer. Cancers. 2019;11(7):1003. doi:10.3390/cancers11071003
   PubMed Web of Science ®Google Scholar
• Kyakulaga AH, Aqil F, Munagala R, et al. Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells. Sci Rep. 2018;8(1):15737. doi:10.1038/s41598-018-34018-1
   PubMed Web of Science ®Google Scholar
• Lin CC, Yang T-Y, Lu H-J, et al. Attenuating role of withaferin A in the proliferation and migration of lung cancer cells via a p53-miR-27a/miR-10b pathway. Oncol Lett. 2021;21(3):232. doi:10.3892/ol.2021.12493
   PubMed Web of Science ®Google Scholar
• Jan YH, Lai T-C, Yang C-J, et al. Adenylate kinase 4 modulates oxidative stress and stabilizes HIF-1α to drive lung adenocarcinoma metastasis. J Hematol Oncol. 2019;12(1):12. doi:10.1186/s13045-019-0698-5
   PubMedGoogle Scholar
• Kyakulaga AH, Aqil F, Munagala R, et al. Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells. Oncotarget. 2020;11(16):1399–1416. doi:10.18632/oncotarget.27519
   PubMedGoogle Scholar
• Cai Y, Sheng Z-Y, Chen Y, et al. Effect of Withaferin A on A549 cellular proliferation and apoptosis in non-small cell lung cancer. Asian Pac J Cancer Prev. 2014;15(4):1711–1714. doi:10.7314/APJCP.2014.15.4.1711
   PubMedGoogle Scholar
• Malik V, Kumar V, Kaul SC, et al. Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers. Biomolecules. 2021;11(2):160. doi:10.3390/biom11020160
   PubMed Web of Science ®Google Scholar
• Liu X, Chen L, Liang T, et al. Withaferin A induces mitochondrial-dependent apoptosis in non-small cell lung cancer cells via generation of reactive oxygen species. J buon. 2017;22(1):244–250.
   PubMed Web of Science ®Google Scholar
• Choudhary MI, Hussain S, Yousuf S, Dar A. Chlorinated and diepoxy withanolides from Withania somnifera and their cytotoxic effects against human lung cancer cell line. Phytochemistry. 2010;71(17–18):2205–2209. doi:10.1016/j.phytochem.2010.08.019
   PubMed Web of Science ®Google Scholar
• Rossato Viana A, Godoy Noro B, Lenz JC, et al. Cytotoxic screening and antibacterial activity of Withaferin A. J Toxicol Environ Health A. 2022;85(16):685–698. doi:10.1080/15287394.2022.2071787
   PubMed Web of Science ®Google Scholar
• Llanos GG, Araujo LM, Jiménez IA, et al. Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells. Eur J Med Chem. 2012;54:499–511. doi:10.1016/j.ejmech.2012.05.032
   PubMed Web of Science ®Google Scholar
• Cohen SM, Mukerji R, Timmermann BN, et al. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Am J Surg. 2012;204(6):895–900. doi:10.1016/j.amjsurg.2012.07.027
   PubMed Web of Science ®Google Scholar
• Shin JA, Kim L-H, Ryu MH, et al. Withaferin A mitigates metastatic traits in human oral squamous cell carcinoma caused by aberrant claudin-1 expression. Cell Biol Toxicol. 2022;38(1):147–165. doi:10.1007/s10565-021-09584-2
   PubMed Web of Science ®Google Scholar
• Panjamurthy K, Manoharan S, Nirmal MR, et al. Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7,12-dimethylbenz(a)anthracene-induced experimental oral carcinogenesis. Invest New Drugs. 2009;27(5):447–452. doi:10.1007/s10637-008-9199-z
   PubMed Web of Science ®Google Scholar
• Yu TJ, Tang J-Y, Ou-Yang F, et al. Low Concentration of Withaferin a Inhibits Oxidative Stress-Mediated Migration and Invasion in Oral Cancer Cells. Biomolecules. 2020;10(5):777. doi:10.3390/biom10050777
   PubMed Web of Science ®Google Scholar
• Peng SY, Wang YY, Lan TH, et al. Low Dose Combined Treatment with Ultraviolet-C and Withaferin a Enhances Selective Killing of Oral Cancer Cells. Antioxidants. 2020;9(11):1120.
   Web of Science ®Google Scholar
• Chang HW, Li R-N, Wang H-R, et al. Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells. Front Physiol. 2017;8:634. doi:10.3389/fphys.2017.00634
   PubMed Web of Science ®Google Scholar
• Samadi AK, Cohen SM, Mukerji R, et al. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation. Tumour Biol. 2012;33(4):1179–1189. doi:10.1007/s13277-012-0363-x
   PubMedGoogle Scholar
• Xu K, Zhang C, Li Y, et al. Withaferin A suppresses skin tumor promotion by inhibiting proteasome-dependent isocitrate dehydrogenase 1 degradation. Transl Cancer Res. 2019;8(6):2449–2460. doi:10.21037/tcr.2019.09.57
   PubMed Web of Science ®Google Scholar
• Li W, Zhao Y. Withaferin A suppresses tumor promoter 12-O-tetradecanoylphorbol 13-acetate-induced decreases in isocitrate dehydrogenase 1 activity and mitochondrial function in skin epidermal JB6 cells. Cancer Sci. 2013;104(2):143–148. doi:10.1111/cas.12051
   PubMed Web of Science ®Google Scholar
• McKenna MK, Gachuki BW, Alhakeem SS, et al. Anti-cancer activity of withaferin A in B-cell lymphoma. Cancer Biol Ther. 2015;16(7):1088–1098. doi:10.1080/15384047.2015.1046651
   PubMed Web of Science ®Google Scholar
• Clesham K, Walf-Vorderwülbecke V, Gasparoli L, et al. Identification of a c-MYB-directed therapeutic for acute myeloid leukemia. Leukemia. 2022;36(6):1541–1549. doi:10.1038/s41375-022-01554-9
   PubMed Web of Science ®Google Scholar
• Yang ES, Choi MJ, Kim JH, et al. Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells. Toxicol In Vitro. 2011;25(8):1803–1810. doi:10.1016/j.tiv.2011.09.016
   PubMed Web of Science ®Google Scholar
• Okamoto S, Tsujioka T, Suemori S-I, et al. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression. Cancer Sci. 2016;107(9):1302–1314. doi:10.1111/cas.12988
   PubMed Web of Science ®Google Scholar
• Malik F, Kumar A, Bhushan S, et al. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis. 2007;12(11):2115–2133. doi:10.1007/s10495-007-0129-x
   PubMed Web of Science ®Google Scholar
• Hassannia B, Wiernicki B, Ingold I, et al. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J Clin Invest. 2018;128(8):3341–3355. doi:10.1172/JCI99032
   PubMed Web of Science ®Google Scholar
• Yco LP, Mocz G, Opoku-Ansah J, et al. Withaferin A Inhibits STAT3 and Induces Tumor Cell Death in Neuroblastoma and Multiple Myeloma. Biochem Insights. 2014;7:1–13. doi:10.4137/BCI.S18863
   PubMedGoogle Scholar
• Tang Q, Ren L, Liu J, et al. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis. Cell Prolif. 2020;53(1):e12706. doi:10.1111/cpr.12706
   PubMed Web of Science ®Google Scholar
• Shah N, Kataria H, Kaul SC, et al. Effect of the alcoholic extract of Ashwagandha leaves and its components on proliferation, migration, and differentiation of glioblastoma cells: combinational approach for enhanced differentiation. Cancer Sci. 2009;100(9):1740–1747. doi:10.1111/j.1349-7006.2009.01236.x
   PubMed Web of Science ®Google Scholar
• Grogan PT, Sleder KD, Samadi AK, et al. Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways. Invest New Drugs. 2013;31(3):545–557. doi:10.1007/s10637-012-9888-5
   PubMed Web of Science ®Google Scholar
• Chang E, Pohling C, Beygui N, et al. Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields. J Neurooncol. 2017;134(2):259–268. doi:10.1007/s11060-017-2534-5
   PubMed Web of Science ®Google Scholar
• Grogan PT, Sarkaria JN, Timmermann BN, et al. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs. 2014;32(4):604–617. doi:10.1007/s10637-014-0084-7
   PubMed Web of Science ®Google Scholar
• Chang E, Pohling C, Natarajan A, et al. AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models. J Neurooncol. 2016;126(2):253–264. doi:10.1007/s11060-015-1972-1
   PubMed Web of Science ®Google Scholar
• Shohat B, Shaltiel A, Ben-Bassat M, et al. The effect of withaferin A, a natural steroidal lactone, on the fine structure of S-180 tumor cells. Cancer Lett. 1976;2(2):71–77. doi:10.1016/S0304-3835(76)80014-6
   PubMed Web of Science ®Google Scholar
• Li AX, Sun M, Li X. Withaferin-A induces apoptosis in osteosarcoma U2OS cell line via generation of ROS and disruption of mitochondrial membrane potential. Eur Rev Med Pharmacol Sci. 2017;21(6):1368–1374.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang Y, Cheryan VT, et al. Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo. PLoS One. 2012;7(8):e41214. doi:10.1371/journal.pone.0041214
   PubMed Web of Science ®Google Scholar
• Nagy Z, Cheung BB, Tsang W, et al. Withaferin A activates TRIM16 for its anti-cancer activity in melanoma. Sci Rep. 2020;10(1):19724. doi:10.1038/s41598-020-76722-x
   PubMed Web of Science ®Google Scholar
• Mayola E, Gallerne C, Esposti DD, et al. Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis. 2011;16(10):1014–1027. doi:10.1007/s10495-011-0625-x
   PubMed Web of Science ®Google Scholar
• Kalthur G, Pathirissery UD. Enhancement of the response of B16F1 melanoma to fractionated radiotherapy and prolongation of survival by withaferin A and/or hyperthermia. Integr Cancer Ther. 2010;9(4):370–377. doi:10.1177/1534735410378664
   PubMed Web of Science ®Google Scholar
• Kalthur G, Mutalik S, Pathirissery UD. Effect of Withaferin A on the development and decay of thermotolerance in B16F1 melanoma: a preliminary study. Integr Cancer Ther. 2009;8(1):93–97. doi:10.1177/1534735408330715
   PubMed Web of Science ®Google Scholar
• Subramanian C, Zhang H, Gallagher R, et al. Withanolides are potent novel targeted therapeutic agents against adrenocortical carcinomas. World J Surg. 2014;38(6):1343–1352. doi:10.1007/s00268-014-2532-0
   PubMed Web of Science ®Google Scholar
• Samadi AK, Tong X, Mukerji R, et al. Withaferin A, a Cytotoxic Steroid from Vassobia breviflora, Induces Apoptosis in Human Head and Neck Squamous Cell Carcinoma. J Nat Prod. 2010;73(9):1476–1481. doi:10.1021/np100112p
   PubMed Web of Science ®Google Scholar
• Kim G, Kim T-H, Hwang E-H, et al. Withaferin A inhibits the proliferation of gastric cancer cells by inducing G2/M cell cycle arrest and apoptosis. Oncol Lett. 2017;14(1):416–422. doi:10.3892/ol.2017.6169
   PubMed Web of Science ®Google Scholar
• Xu K, Shi H, Du Y, Ou J. Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling. Biotech. 2021;11(7):323.
   Google Scholar
• Liu X, Li Y, Ma Q, et al. Withaferin-A Inhibits Growth of Drug-Resistant Breast Carcinoma by Inducing Apoptosis and Autophagy, Endogenous Reactive Oxygen Species (ROS) Production, and Inhibition of Cell Migration and Nuclear Factor kappa B (Nf-κB)/Mammalian Target of Rapamycin (m-TOR) Signalling Pathway. Med Sci Monit. 2019;25:6855–6863. doi:10.12659/MSM.916931
   PubMed Web of Science ®Google Scholar
• Kim SH, Hahm E-R, Arlotti JA, et al. Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown. Breast Cancer Res Treat. 2016;157(1):41–54. doi:10.1007/s10549-016-3795-y
   PubMed Web of Science ®Google Scholar
• Ur Rasool R, Rah B, Amin H, et al. Dual modulation of Ras-Mnk and PI3K-AKT-mTOR pathways: a Novel c-FLIP inhibitory mechanism of 3-AWA mediated translational attenuation through dephosphorylation of eIF4E. Sci Rep. 2016;6(1):18800. doi:10.1038/srep18800
   PubMedGoogle Scholar
• Yang Z, Garcia A, Xu S, et al. Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. PLoS One. 2013;8(9):e75069. doi:10.1371/journal.pone.0075069
   PubMed Web of Science ®Google Scholar
• Samanta SK, Sehrawat A, Kim S-H, et al. Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A. J Natl Cancer Inst. 2017;109(6):djw293. doi:10.1093/jnci/djw293
   PubMedGoogle Scholar
• Yang H, Shi G, Dou QP. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from “Indian winter cherry”. Mol Pharmacol. 2007;71(2):426–437. doi:10.1124/mol.106.030015
   PubMed Web of Science ®Google Scholar
• Suman S, Das TP, Moselhy J, et al. Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model. Oncotarget. 2016;7(33):53751–53761. doi:10.18632/oncotarget.10733
   PubMedGoogle Scholar
• Chandrasekaran B, Pal D, Kolluru V, et al. The chemopreventive effect of withaferin A on spontaneous and inflammation-associated colon carcinogenesis models. Carcinogenesis. 2018;39(12):1537–1547. doi:10.1093/carcin/bgy109
   PubMed Web of Science ®Google Scholar
• Kuppusamy P, Nagalingam A, Muniraj N, et al. Concomitant activation of ETS-like transcription factor-1 and Death Receptor-5 via extracellular signal-regulated kinase in withaferin A-mediated inhibition of hepatocarcinogenesis in mice. Sci Rep. 2017;7(1):17943. doi:10.1038/s41598-017-18190-4
   PubMedGoogle Scholar
• Kunimasa K, Nagano T, Shimono Y, et al. Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters. Cancer Sci. 2017;108(7):1368–1377. doi:10.1111/cas.13266
   PubMed Web of Science ®Google Scholar
• Samadi AK, Mukerji R, Shah A, et al. A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo. Surgery. 2010;148(6):1228–1236. doi:10.1016/j.surg.2010.09.026
   PubMed Web of Science ®Google Scholar
• Manoharan S, Panjamurthy K, Balakrishnan S, et al. Circadian time-dependent chemopreventive potential of withaferin-A in 7,12-dimethylbenz[a]anthracene-induced oral carcinogenesis. Pharmacol Rep. 2009;61(4):719–726. doi:10.1016/S1734-1140(09)70125-2
   PubMed Web of Science ®Google Scholar
• Manoharan S, Panjamurthy K, Menon VP, et al. Protective effect of Withaferin-A on tumour formation in 7,12-dimethylbenz[a]anthracene induced oral carcinogenesis in hamsters. Indian J Exp Biol. 2009;47(1):16–23.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang C, Du H, et al. Withaferin A suppresses the up-regulation of acetyl-coA carboxylase 1 and skin tumor formation in a skin carcinogenesis mouse model. Mol Carcinog. 2016;55(11):1739–1746. doi:10.1002/mc.22423
   PubMed Web of Science ®Google Scholar
• Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, et al. Synergistic antileukemic therapies in NOTCH1 -induced T-ALL. Proc Natl Acad Sci U S A. 2017;114(8):2006–2011. doi:10.1073/pnas.1611831114
   PubMed Web of Science ®Google Scholar
• Amin H, Nayak D, Ur Rasool R, et al. Par-4 dependent modulation of cellular β-catenin by medicinal plant natural product derivative 3-azido Withaferin A. Mol Carcinog. 2016;55(5):864–881. doi:10.1002/mc.22328
   PubMed Web of Science ®Google Scholar
• Agarwalla P, Mukherjee S, Sreedhar B, et al. Glucocorticoid receptor-mediated delivery of nano gold-withaferin conjugates for reversal of epithelial-to-mesenchymal transition and tumor regression. Nanomedicine. 2016;11(19):2529–2546. doi:10.2217/nnm-2016-0224
   PubMed Web of Science ®Google Scholar
• Uma Devi P, Kamath R. Radiosensitizing effect of withaferin A combined with hyperthermia on mouse fibrosarcoma and melanoma. J Radiat Res. 2003;44(1):1–6. doi:10.1269/jrr.44.1
   PubMed Web of Science ®Google Scholar
• Sharada AC, Solomon FE, Devi PU, et al. Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol. 1996;35(1):95–100. doi:10.3109/02841869609098486
   PubMed Web of Science ®Google Scholar
• Devi PU, Sharada AC, Solomon FE. In vivo growth inhibitory and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma. Cancer Lett. 1995;95(1–2):189–193. doi:10.1016/0304-3835(95)03892-Z
   PubMed Web of Science ®Google Scholar
• Shohat B, Joshua H. Effect of withaferin A on Ehrlich ascites tumor cells. II. Target tumor cell destruction in vivo by immune activation. Int J Cancer. 1971;8(3):487–496. doi:10.1002/ijc.2910080317
   PubMed Web of Science ®Google Scholar
• Gupta RC, Bansal SS, Aqil F, et al. Controlled-release systemic delivery - A new concept in cancer chemoprevention. Carcinogenesis. 2012;33(8):1608–1615. doi:10.1093/carcin/bgs209
   PubMed Web of Science ®Google Scholar
• Pires N, Gota V, Gulia A, et al. Safety and pharmacokinetics of Withaferin-A in advanced stage high grade osteosarcoma: a phase I trial. J Ayurveda Integr Med. 2020;11(1):68–72. doi:10.1016/j.jaim.2018.12.008
   PubMed Web of Science ®Google Scholar
• Malik V, Radhakrishnan N, Kaul SC, et al. Computational Identification of BCR-ABL Oncogenic Signaling as a Candidate Target of Withaferin A and Withanone. Biomolecules. 2022;12(2):212. doi:10.3390/biom12020212
   PubMed Web of Science ®Google Scholar
• Kalra RS, Kumar V, Dhanjal JK, et al. COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays. J Biomol Struct Dyn. 2022;40(17):7885–7898. doi:10.1080/07391102.2021.1902858
   PubMed Web of Science ®Google Scholar
• Surya Ulhas R, Malaviya A. In-silico validation of novel therapeutic activities of withaferin a using molecular docking and dynamics studies. J Biomol Struct Dyn. 2022;1–12. doi:10.1080/07391102.2022.2078410
   Web of Science ®Google Scholar
• Bargagna-Mohan P, Hamza A, Kim Y-E, et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol. 2007;14(6):623–634. doi:10.1016/j.chembiol.2007.04.010
   PubMedGoogle Scholar
• Falsey RR, Marron MT, Gunaherath GMKB, et al. Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol. 2006;2(1):33–38. doi:10.1038/nchembio755
   PubMed Web of Science ®Google Scholar
• Ozorowski G, Ryan CM, Whitelegge JP, et al. Withaferin A binds covalently to the N-terminal domain of annexin A2. Biol Chem. 2012;393(10):1151–1163. doi:10.1515/hsz-2012-0184
   PubMed Web of Science ®Google Scholar
• Stewart JA, Bhagwat AS. A redox-sensitive iron-sulfur cluster in murine FAM72A controls its ability to degrade the nuclear form of uracil-DNA glycosylase. DNA Repair (Amst). 2022;118:103381. doi:10.1016/j.dnarep.2022.103381
   PubMed Web of Science ®Google Scholar
• Vanden Berghe W, Sabbe L, Kaileh M, et al. Molecular insight in the multifunctional activities of Withaferin A. Biochem Pharmacol. 2012;84(10):1282–1291. doi:10.1016/j.bcp.2012.08.027
   PubMed Web of Science ®Google Scholar
• Lee I-C, Choi BY. Withaferin-A--A Natural Anticancer Agent with Pleitropic Mechanisms of Action. Int J Mol Sci. 2016;17(3):290. doi:10.3390/ijms17030290
   PubMed Web of Science ®Google Scholar
• Chirumamilla CS, Pérez-Novo C, Van Ostade X, et al. Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A. Proc Nutr Soc. 2017;76(2):96–105. doi:10.1017/S0029665116002937
   PubMed Web of Science ®Google Scholar
• Stan SD, Zeng Y, Singh SV. Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer. 2008;60(Suppl 1):51–60. doi:10.1080/01635580802381477
   PubMedGoogle Scholar
• Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000;102(1):1–4. doi:10.1016/S0092-8674(00)00003-9
   PubMed Web of Science ®Google Scholar
• Anichini A, Mortarini R, Sensi M, et al. APAF-1 signaling in human melanoma. Cancer Lett. 2006;238(2):168–179. doi:10.1016/j.canlet.2005.06.034
   PubMed Web of Science ®Google Scholar
• Mandal C, Dutta A, Mallick A, et al. Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis. 2008;13(12):1450–1464. doi:10.1007/s10495-008-0271-0
   PubMed Web of Science ®Google Scholar
• Ichikawa H, Takada Y, Shishodia S, et al. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther. 2006;5(6):1434–1445. doi:10.1158/1535-7163.MCT-06-0096
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang L, Yang H, et al. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 2007;67(19):9425–9434. doi:10.1158/0008-5472.CAN-07-1310
   PubMed Web of Science ®Google Scholar
• Krueger A, Schmitz I, Baumann S, et al. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem. 2001;276(23):20633–20640. doi:10.1074/jbc.M101780200
   PubMed Web of Science ®Google Scholar
• Fukazawa T, Fujiwara T, Uno F, et al. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene. 2001;20(37):5225–5231. doi:10.1038/sj.onc.1204673
   PubMed Web of Science ®Google Scholar
• Woo SM, Min K-J, Kim S, et al. Axl is a novel target of withaferin A in the induction of apoptosis and the suppression of invasion. Biochem Biophys Res Commun. 2014;451(3):455–460. doi:10.1016/j.bbrc.2014.08.018
   PubMed Web of Science ®Google Scholar
• Li L, Niu B, Zhang W, et al. Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis. Acta Biochim Pol. 2022;69(1):197–203. doi:10.18388/abp.2020_5938
   PubMed Web of Science ®Google Scholar
• Su M, Mei Y, Sinha S. Role of the Crosstalk between Autophagy and Apoptosis in Cancer. J Oncol. 2013;2013:102735. doi:10.1155/2013/102735
   PubMedGoogle Scholar
• Bommareddy A, Hahm E-R, Xiao D, et al. Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res. 2009;69(8):3704–3712. doi:10.1158/0008-5472.CAN-08-4344
   PubMed Web of Science ®Google Scholar
• Jung YY, Um J-Y, Chinnathambi A, et al. Withanolide modulates the potential crosstalk between apoptosis and autophagy in different colorectal cancer cell lines. Eur J Pharmacol. 2022;928:175113. doi:10.1016/j.ejphar.2022.175113
   PubMed Web of Science ®Google Scholar
• Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35(6):830–849. doi:10.1016/j.ccell.2019.04.002
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg K, Lamprecht M, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042
   PubMed Web of Science ®Google Scholar
• Brigelius-Flohé R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta. 2013;1830(5):3289–3303. doi:10.1016/j.bbagen.2012.11.020
   PubMed Web of Science ®Google Scholar
• Logie E, Novo CP, Driesen A, et al. Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells. Int J Mol Sci. 2021;22(23):12731. doi:10.3390/ijms222312731
   PubMed Web of Science ®Google Scholar
• Nishi M, Akutsu H, Kudoh A, et al. Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell. Oncotarget. 2014;5(18):8665–8680. doi:10.18632/oncotarget.2356
   PubMed Web of Science ®Google Scholar
• Bolós V, Peinado H, Perez-Moreno MA, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116(Pt 3):499–511. doi:10.1242/jcs.00224
   PubMed Web of Science ®Google Scholar
• Winter M, Meignan S, Völkel P, et al. Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment. Cells. 2021;10(6):1504. doi:10.3390/cells10061504
   PubMed Web of Science ®Google Scholar
• Chaudhary A, Kalra RS, Malik V, et al. 2, 3-Dihydro-3β-methoxy Withaferin-A Lacks Anti-Metastasis Potency: bioinformatics and Experimental Evidences. Sci Rep. 2019;9(1):17344. doi:10.1038/s41598-019-53568-6
   PubMedGoogle Scholar
• Mohan R, Hammers H, Bargagna-mohan P, et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7(2):115–122. doi:10.1007/s10456-004-1026-3
   PubMedGoogle Scholar
• Prasanna KS, Shilpa P, Salimath BP. Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor. Curr Trends Biotechnol Pharm. 2009;3(2):138–148.
   Google Scholar
• Saha S, Islam MK, Shilpi JA, et al. Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera’s key metabolite Withaferin A. Silico Pharmacol. 2013;1(1):11. doi:10.1186/2193-9616-1-11
   PubMedGoogle Scholar
• Wang Y-X, Ding W-B, Dong C-W. Withaferin A Suppresses Liver Tumor Growth in a Nude Mouse Model by Downregulation of Cell Signaling Pathway Leading to Invasion and Angiogenesis. Trop J Pharm Res. 2015;14(6):1005–1011. doi:10.4314/tjpr.v14i6.10
   Web of Science ®Google Scholar
• Gao R, Shah N, Lee J-S, et al. Withanone-rich combination of Ashwagandha withanolides restricts metastasis and angiogenesis through hnRNP-K. Mol Cancer Ther. 2014;13(12):2930–2940. doi:10.1158/1535-7163.MCT-14-0324
   PubMed Web of Science ®Google Scholar
• Rah B, Amin H, Yousuf K, et al. A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. PLoS One. 2012;7(9):e44039. doi:10.1371/journal.pone.0044039
   PubMed Web of Science ®Google Scholar
• Royston KJ, Udayakumar N, Lewis K, et al. A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells. Int J Mol Sci. 2017;18(5):1092. doi:10.3390/ijms18051092
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tan Y, Liu S. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis. Toxicol Mech Methods. 2022;1–9.
   Web of Science ®Google Scholar
• Makol A, Kaur H, Sharma S, et al. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line. Clin Mol Hepatol. 2020;26(1):45–53. doi:10.3350/cmh.2019.0031
   PubMed Web of Science ®Google Scholar
• Maxwell SA, Cherry EM, Bayless KJ. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52(5):849–864. doi:10.3109/10428194.2010.551793
   PubMed Web of Science ®Google Scholar
• Mandlik Ingawale DS, Namdeo AG. Pharmacological evaluation of Ashwagandha highlighting its healthcare claims, safety, and toxicity aspects. J Diet Suppl. 2021;18(2):183–226. doi:10.1080/19390211.2020.1741484
   PubMed Web of Science ®Google Scholar
• Devi PU, Sharada AC, Solomon FE, et al. In vivo growth inhibitory effect of Withania somnifera (Ashwagandha) on a transplantable mouse tumor, Sarcoma 180. Indian J Exp Biol. 1992;30(3):169–172.
   PubMedGoogle Scholar
• Gupta SK, Jadhav S, Gohil D, et al. Safety, toxicity and pharmacokinetic assessment of oral Withaferin-A in mice. Toxicol Rep. 2022;9:1204–1212. doi:10.1016/j.toxrep.2022.05.012
   PubMedGoogle Scholar
• Shohat B, Gitter S, Abraham A, et al. Antitumor activity of withaferin A (NSC-101088). Cancer Chemother Rep. 1967;51(5):271–276.
   PubMedGoogle Scholar
• Shohat B, Gitter S, Lavie D. Effect of withaferin A on Ehrlich ascites tumor cells--cytological observations. Int J Cancer. 1970;5(2):244–252. doi:10.1002/ijc.2910050212
   PubMed Web of Science ®Google Scholar
• Tyagi A, Kolluru V, Chandrasekaran B, et al. ASR488, a novel small molecule, activates an mRNA binding protein, CPEB1, and inhibits the growth of bladder cancer. Oncol Lett. 2020;20(1):850–860. doi:10.3892/ol.2020.11593
   PubMed Web of Science ®Google Scholar
• Zhang H, Samadi AK, Cohen MS, et al. Anti-proliferative withanolides from the Solanaceae: a structure-activity study. Pure Appl Chem. 2012;84(6):1353–1367. doi:10.1351/PAC-CON-11-10-08
   PubMed Web of Science ®Google Scholar
• Tyagi A, Chandrasekaran B, Kolluru V, et al. ASR490, a Small Molecule, Overrides Aberrant Expression of Notch1 in Colorectal Cancer. Mol Cancer Ther. 2020;19(12):2422–2431. doi:10.1158/1535-7163.MCT-19-0949
   PubMed Web of Science ®Google Scholar
• Dai T, Jiang W, Guo Z, et al. Studies on oral bioavailability and first-pass metabolism of withaferin A in rats using LC-MS/MS and Q-TRAP. Biomed Chromatogr. 2019;33(9):e4573. doi:10.1002/bmc.4573
   PubMed Web of Science ®Google Scholar
• Aqil F, Jeyabalan J, Kausar H, et al. Multi-layer polymeric implants for sustained release of chemopreventives. Cancer Lett. 2012;326(1):33–40. doi:10.1016/j.canlet.2012.07.017
   PubMed Web of Science ®Google Scholar
• Akram M, Shah SA. Monograph. Withania somnifera. Altern Med Rev. 2004;9(2):211–214.
   PubMedGoogle Scholar
• Sharada M, Ahuja A, Vij SP. Application of Biotechnology in Indian Ginseng (Ashwagandha): progress and prospects. Recent Adv Plant Tissue Culture Appl. 2008;1:67.
   Google Scholar
• Ankad GM, Pai SR, Hiremath J, et al. Traditional Horticulture Practices Increase the Production of Selected Withanolides in Withania Somnifera (L.) Dunal-A RP-UFLC Analysis. J Chromatogr Sci. 2020;58(10):899–906. doi:10.1093/chromsci/bmaa057
   PubMed Web of Science ®Google Scholar
• Singh M, Agrawal S, Afzal O, et al. Optimization of Elicitation Conditions to Enhance the Production of Potent Metabolite Withanolide from Withania somnifera (L.). Metabolites. 2022;12(9):854. doi:10.3390/metabo12090854
   PubMed Web of Science ®Google Scholar
• Tripathi D, Meena RP, Pandey-Rai S. Short term UV-B radiation mediated modulation of physiological traits and withanolides production in Withania coagulans (L.) Dunal under in-vitro condition. Physiol Mol Biol Plants. 2021;27(8):1823–1835. doi:10.1007/s12298-021-01046-7
   PubMed Web of Science ®Google Scholar
• Tripathi D, Rai KK, Pandey-Rai S. Impact of green synthesized WcAgNPs on in-vitro plant regeneration and withanolides production by inducing key biosynthetic genes in Withania coagulans. Plant Cell Rep. 2021;40(2):283–299. doi:10.1007/s00299-020-02630-z
   PubMed Web of Science ®Google Scholar
• Pandey SS, Singh S, Pandey H, et al. Endophytes of Withania somnifera modulate in planta content and the site of withanolide biosynthesis. Sci Rep. 2018;8(1):5450. doi:10.1038/s41598-018-23716-5
   PubMedGoogle Scholar
• Grover A, Samuel G, Bisaria VS, et al. Enhanced withanolide production by overexpression of squalene synthase in Withania somnifera. J Biosci Bioeng. 2013;115(6):680–685. doi:10.1016/j.jbiosc.2012.12.011
   PubMed Web of Science ®Google Scholar
• Mishra S, Bansal S, Mishra B, et al. RNAi and Homologous Over-Expression Based Functional Approaches Reveal Triterpenoid Synthase Gene-Cycloartenol Synthase Is Involved in Downstream Withanolide Biosynthesis in Withania somnifera. PLoS One. 2016;11(2):e0149691. doi:10.1371/journal.pone.0149691
   PubMed Web of Science ®Google Scholar
• Sivanandhan G, Kapil Dev G, Theboral J, et al. Sonication, Vacuum Infiltration and Thiol Compounds Enhance the Agrobacterium-Mediated Transformation Frequency of Withania somnifera (L.) Dunal. PLoS One. 2015;10(4):e0124693. doi:10.1371/journal.pone.0124693
   PubMed Web of Science ®Google Scholar
• Ray S, Jha S. Production of withaferin A in shoot cultures of Withania somnifera. Planta Med. 2001;67(5):432–436. doi:10.1055/s-2001-15811
   PubMed Web of Science ®Google Scholar
• Sivanandhan G, Arun M, Mayavan S, et al. Chitosan enhances withanolides production in adventitious root cultures of Withania somnifera (L.) Dunal. Ind Crops Prod. 2012;37(1):124–129. doi:10.1016/j.indcrop.2011.11.022
   Web of Science ®Google Scholar
• Sivanandhan G, Kapil Dev G, Jeyaraj M, et al. Increased production of withanolide A, withanone, and withaferin A in hairy root cultures of Withania somnifera (L.) Dunal elicited with methyl jasmonate and salicylic acid. Plant Cell Tissue Organ Cult. 2013;114(1):121–129. doi:10.1007/s11240-013-0297-z
   Web of Science ®Google Scholar
• Sivanandhan G, Kapil Dev G, Jeyaraj M, et al. A promising approach on biomass accumulation and withanolides production in cell suspension culture of Withania somnifera (L.) Dunal. Protoplasma. 2013;250(4):885–898. doi:10.1007/s00709-012-0471-x
   PubMed Web of Science ®Google Scholar
• Ciddi VJ. Withaferin A from cell cultures of Withania somnifera. Indian J Pharm Sci. 2006;68(4).
   Google Scholar